Abstract: An electronic device may have a hinge that allows the device to be flexed about a bend axis. A display may span the bend axis. The device may have a stainless steel and/or carbon fiber reinforced polymer layer with slots. The slots may overlap the bend axis. The slots may have at least one property that varies in a non-linear manner as a function of position on the layer. The device may include an adhesive layer with a cutout that overlaps the slots. An interface that defines the cutout may have a plurality of recesses with varying depths. A flexible printed circuit may be attached to an edge of the display panel. The display cover layer may overlap a bonding region between the flexible printed circuit and the edge of the display panel. A UV-curable gap filler may be interposed between the flexible printed circuit and the display cover layer.

Abstract: An electronic device may have a hinge that allows the device to be flexed about a bend axis. A display may span the bend axis. The device may have a stainless steel and/or carbon fiber reinforced polymer layer with slots. The slots may overlap the bend axis. The slots may have at least one property that varies in a non-linear manner as a function of position on the layer. The device may include an adhesive layer with a cutout that overlaps the slots. An interface that defines the cutout may have a plurality of recesses with varying depths. A flexible printed circuit may be attached to an edge of the display panel. The display cover layer may overlap a bonding region between the flexible printed circuit and the edge of the display panel. A UV-curable gap filler may be interposed between the flexible printed circuit and the display cover layer.

Abstract: The present disclosure provides a hydraulic phosphogypsum (PG)-based cementitious material, and a preparation method and use thereof, belonging to the technical field of cementitious materials. The present disclosure provides a hydraulic PG-based cementitious material, including the following raw materials: modified PG particles and an auxiliary active powder, where the modified PG particles have a dosage of 50 wt % to 95 wt %; the modified PG particles are obtained by conducting modification on original PG particles through a calcareous material, and the calcareous material has a mass 3% to 5% of that of the original PG particles; and the original PG particles have typical dimensions of: a length of 50 ?m to 200 ?m and an aspect ratio of 1.5 to 5; and at least 80% of materials in the auxiliary active powder have a particle size of less than or equal to 60 ?m. In the present disclosure, the hydraulic PG-based cementitious material adopts a particle accumulation method of gap grading.

Abstract: A non-sintered high-strength lightweight aggregate one-shot prepared from sulfur-based and alkaline-based solid wastes by stirring, granulation, and foaming, and a preparation method therefor and use thereof. The non-sintered high-strength lightweight aggregate is prepared from a sulfur-based solid waste, an alkaline-based solid waste, an auxiliary cementing material, a ferro-aluminum-sulfur cementing material, water, and a foaming agent as raw materials. Based on the mass of the total solid, the total content of the sulfur-based solid waste, the alkaline-based solid waste, and the auxiliary cementing material is 80-90 wt %, and the content of the ferro-aluminum-sulfur cementing material is 10-20 wt %. The mass ratio of the water to the total solid is (15-20):(80-85). The foaming agent accounts for 0.3-0.7% of the mass of the total solid. The mass ratio between the sulfur-based solid waste, the alkaline-based solid waste, and the auxiliary cementing material is (27-33):(27-33):(18-25).

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Abstract: A package substrate is provided, in which a second dielectric layer with a smaller CTE and a third dielectric layer with a larger CTE are formed on two opposite sides of a wiring structure including a first dielectric layer, respectively, so as to avoid too large a difference in CTE of the wiring structure between two sides thereof, thereby preventing warpage from occurring to the package substrate.

Abstract: In devices with flexible displays, multilayer adhesive stacks may be included. A multilayer adhesive may attach a flexible display panel to the display cover layer in an electronic device. Including multiple layers of adhesive in the adhesive stack (as opposed to a single layer) provides more degrees of freedom for the tuning and optimization of the properties of the adhesive stack. The multilayer adhesive stack therefore has better performance than if only a single layer of adhesive is used. The multilayer adhesive stack may include one or more layers of soft adhesive, hard adhesive, hard elastomer, hard polymer, and/or glass to optimize the mechanical and optical performance of the multilayer adhesive stack. Soft adhesive layers may be included to optimize lateral decoupling (e.g., during folding and unfolding) of the adhesive stack. Harder layers may be included to provide rigidity and prevent denting during impact events.

Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Abstract: The application provides a method for data reading and writing processing, data center, disaster recovery system and storage medium. The method includes receiving, by a first data center, a data reading request including a first user identification; determining, in response to the data reading request, whether a writing user identification set stored in the first data center includes the first user identification, the writing user identification set including user identifications corresponding to data writing requests; and under a condition that the writing user identification set includes the first user identification, forwarding the data reading request to a second data center, to read, in the second data center, data to be read as indicated by the data reading request, the second data center being configured to receive and process a data writing request sent by a user terminal or forwarded by the first data center.

Abstract: The present disclosure discloses a design method for lightweight wired Mesh networking. The design method includes: designing a protocol format of a lightweight wired Mesh network message; designing an input parsing module of the lightweight wired Mesh network message; designing a heartbeat logic module between devices of the lightweight wired Mesh networking; designing a route management module of a lightweight wired Mesh network; designing a forwarding and processing module of the lightweight wired Mesh network message; and designing an underlying hardware interface management module.

Abstract: A portable electronic device can include a housing defining an aperture and a display positioned in the aperture. The portable electronic device can include a number of components that can provide desired functionalities and levels of performance. For example, the device can include one or more couplers that interconnect various portions of the housing together. Additionally or alternatively, the portable electronic device can include one or more millimeter-wave antennas. Additionally, or alternatively, the electronic device can include one or more grounding elements or layers that reliably and electrically ground the display to the housing.

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Abstract: The invention describes products, uses thereof, compositions thereof, and methods to prepare products formed from Maillard reaction products from a sugar donor and/or sweet tea extracts, stevia extracts, swingle (mogroside) extracts, one or more sweet tea extract components, one or more steviol glycosides, one or more mogrosides, one or more glycosylated sweet tea glycosides, one or more glycosylated steviol glycosides or one or more glycosylated mogrosides and an amine donor/reactant.

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Abstract: The present invention discloses a modular intelligent combined wind power converter and a control method thereof. The modular intelligent combined wind power converter comprises separate bridge arm power units, wherein a plurality of the bridge arm power units are connected in parallel to form a high-capacity bridge arm power module, three bridge arm power modules form a three-phase full-controlled bridge power module, and the three-phase full-controlled bridge power module comprises an electric reactor, a capacitor, a fuse and a circuit breaker to form a basic converter module, and the basic converter module forms a high-capacity wind power converter through a modular intelligent combination method.

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Abstract: The invention describes products, uses thereof, compositions thereof, and methods to prepare products formed from Maillard reaction products from a sugar donor and/or sweet tea extracts, stevia extracts, swingle (mogroside) extracts, one or more sweet tea extract components, one or more steviol glycosides, one or more mogrosides, one or more glycosylated sweet tea glycosides, one or more glycosylated steviol glycosides or one or more glycosylated mogrosides and an amine donor/reactant.

Abstract: The invention describes products, uses thereof, compositions thereof, and methods to prepare products formed from Maillard reaction products from a sugar donor and/or sweet tea extracts, stevia extracts, swingle (mogroside) extracts, one or more sweet tea extract components, one or more steviol glycosides, one or more mogrosides, one or more glycosylated sweet tea glycosides, one or more glycosylated steviol glycosides or one or more glycosylated mogrosides and an amine donor/reactant.

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.